Document is current

Article History

Accepted: 11 September 2021

First Online: 7 October 2021

Declarations

:

: The study was approved by the Institutional Review Board (IRB) at the Icahn School of Medicine at Mount Sinai in May 2020 and determined to be exempt with a waiver of informed consent (HS#: 20-00435| GCO#1:20-0930(0001) ISMMS).

: This study was deemed by the IRB at ISMMS to have a waiver of informed consent. All participants accessed a form at the beginning of each survey informing them that their responses were collected for use in a research study. No identifying information was collected for this study.

: Dr. Charney is named as co-inventor on patents filed by the Icahn School of Medicine at Mount Sinai (ISMMS) relating to the treatment for treatment-resistant depression, suicidal ideation and other disorders. ISMMS has entered into a licensing agreement with Janssen Pharmaceuticals, Inc. and it has and will receive payments from Janssen under the license agreement related to these patents for the treatment of treatment-resistant depression and suicidal ideation. Consistent with the ISMMS Faculty Handbook (the medical school policy), Dr. Charney is entitled to a portion of the payments received by the ISMMS. Since SPRAVATO has received regulatory approval for treatment-resistant depression, ISMMS and thus, through the ISMMS, Dr. Charney, will be entitled to additional payments, beyond those already received, under the license agreement. Dr. Charney is a named co-inventor on several patents filed by ISMMS for a cognitive training intervention to treat depression and related psychiatric disorders. The ISMMS has entered into a licensing agreement with Click Therapeutics, Inc. and has and will receive payments related to the use of this cognitive training intervention for the treatment of psychiatric disorders. In accordance with the ISMMS Faculty Handbook, Dr. Charney has received a portion of these payments and is entitled to a portion of any additional payments that the medical school might receive from this license with Click Therapeutics. Dr. Charney is a named co-inventor on a patent application filed by the ISMMS for the use of intranasally administered Neuropeptide Y (NPY) for the treatment of mood and anxiety disorders. This intellectual property has not been licensed. Dr. Charney is a named co-inventor on a patent application in the US, and several issued patents outside the US filed by the ISMMS related to the use of ketamine for the treatment of post-traumatic stress disorder (PTSD). This intellectual property has not been licensed. No other declarations of interest to disclose.

Free to read: This content has been made available to all.